RBC Europe’s Novo Nordisk NVO Stock Holding History

RBC Europe’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$56K	Hold	1,006	–	–	﹤0.01%	318
2022 Q1	$56K	Hold	1,006	–	–	﹤0.01%	335
2021 Q4	$56K	Sell	1,006 -1,890	-65%	-$102K	﹤0.01%	349
2021 Q3	$139K	Hold	2,896	–	–	0.01%	358
2021 Q2	$121K	Hold	2,896	–	–	0.01%	397
2021 Q1	$97.6K	Buy	2,896 +400	+16%	+$14.2K	0.01%	409
2020 Q4	$87.2K	Hold	2,496	–	–	0.01%	410
2020 Q3	$86.6K	Hold	2,496	–	–	0.01%	373
2020 Q2	$81.7K	Hold	2,496	–	–	0.01%	360
2020 Q1	$75.1K	Hold	2,496	–	–	0.01%	336
2019 Q4	$72.2K	Hold	2,496	–	–	0.01%	391
2019 Q3	$64.5K	Buy	2,496 +448	+22%	+$11.3K	0.01%	404
2019 Q2	$52.3K	Hold	2,048	–	–	0.01%	441
2019 Q1	$53.6K	Sell	2,048 -142	-6%	-$3.49K	0.01%	442
2018 Q4	$50.4K	Hold	2,190	–	–	0.01%	433
2018 Q3	$51.6K	Hold	2,190	–	–	0.01%	465
2018 Q2	$50.5K	Hold	2,190	–	–	0.01%	459
2018 Q1	$53.9K	Hold	2,190	–	–	0.01%	447
2017 Q4	$58.8K	Hold	2,190	–	–	0.01%	446
2017 Q3	$52.7K	Buy	+2,190	New	+$49.5K	0.01%	460

Other funds holding NVO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RBC Europe's NVO Position: Q2 2022 in Review

RBC Europe held its Novo Nordisk (NVO) position steady in Q2 2022 at 1,006 shares worth $56K. The position accounts for ﹤0.01% of the portfolio, ranked #318.

RBC Europe first reported a position in NVO in Q3 2017 and has held it in 20 quarters since. The position peaked at $139K in Q3 2021. 932 funds tracked by Wall St. Rank hold NVO as of Q2 2022.

RBC Europe held 1,006 shares of Novo Nordisk worth $56K as of Q2 2022.
RBC Europe left its Novo Nordisk share count unchanged in Q2 2022.
Novo Nordisk made up ﹤0.01% of RBC Europe's portfolio in Q2 2022, its #318 holding.
RBC Europe first reported a position in Novo Nordisk in Q3 2017 and has held it in 20 quarters since.
RBC Europe's Novo Nordisk position peaked at $139K in Q3 2021.
932 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2022.

Based on RBC Europe's 13F filing for Q2 2022, filed 14 Nov 2022.